DOI 10.20398/jscr.v15i1.35636

POST-ACUTE COVID-19 SYNDROME AND STROKE

Amália Cinthia Meneses do Rêgo[1], Irami Araújo-Filho[2]

1. Institute of Teaching, Research, and Innovation, Liga Contra o Câncer – Natal – Brazil; ORCID: https://orcid.org/0000-0002-0575-3752; Full Professor of the Postgraduate Program in Biotechnology at Potiguar University, Potiguar University (UnP) – Natal/RN - Brazil. E-mail: regoamalia@gmail.com;
2. Institute of Teaching, Research, and Innovation, Liga Contra o Câncer – Natal – Brazil; ORCID: https://orcid.org/0000-0003-2471-7447; Full Professor of the Postgraduate Program in Biotechnology at Potiguar University (UnP) – Natal/RN - Brazil. Full Professor, Department of Surgery, Potiguar University. Ph.D. in Health Science/ Natal-RN - Brazil. E-mail: irami.filho@uol.com.br

Study performed Postgraduate Program in Biotechnology at Potiguar University/ UnP.
Financial support: None.
Conflicts of interest: None.
Address for correspondence Av. Hermes da Fonseca, 1444 - Apto. 1302 - Tirol - Natal - State of Rio Grande do Norte - Brazil.Zip code: 59020-650.Phone: +55 84 98876-0206.
E-mail: irami.filho@uol.com.br.
Submitted: feb 21; accepted after revision, apr 29, 2024.

ABSTRACT

This review explores the multifaceted strategies to mitigate the risk of cerebrovascular impairment in young adults recovering from COVID-19. The pandemic has illuminated an increased incidence of stroke in populations traditionally considered at lower risk, underscoring the need for targeted preventative measures. Given the complex interplay between SARS-CoV-2 infection and stroke risk, this article synthesizes current evidence and recommendations across lifestyle modifications, medical interventions, and proactive health monitoring. Key recommendations include adopting a heart-healthy diet, engaging in regular physical activity, and implementing stress reduction techniques. The management of existing cardiovascular risk factors, such as hypertension and diabetes, is emphasized as crucial for minimizing stroke risk post-COVID. Moreover, education on recognizing stroke symptoms is vital for ensuring timely medical response. The review also discusses the importance of avoiding smoking, limiting alcohol intake, and, for specific high-risk individuals, the judicious use of anticoagulants. Regular medical follow-ups for monitoring post-COVID symptoms and addressing any ongoing complications are advocated to identify and manage potential risks early. In conclusion, a comprehensive approach involving lifestyle changes, vigilant management of pre-existing conditions, education on stroke symptoms, and regular healthcare engagement is essential for reducing the risk of cerebrovascular events in

young adults recovering from COVID-19. This review underscores the importance of continued research and public health advocacy in addressing the long-term effects of the pandemic on cerebrovascular health.

Keywords: post-acute Covid-19 syndrome; long Covid; long-haul Covid; stroke; acute cerebrovascular accident; cerebrovascular strokes.

INTRODUCTION

The ongoing global COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a spectrum of clinical manifestations, ranging from asymptomatic or mild respiratory symptoms to severe pneumonia and multi-organ dysfunction[1].

The interplay between Post-Acute COVID-19 Syndrome, often referred to as "Long COVID," and cerebrovascular accidents, or strokes, represents a critical frontier in contemporary medical research. The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has not only led to acute respiratory distress and mortality but also to long-term sequelae affecting various organ systems, including the cardiovascular and cerebrovascular systems[1]. This article aims to explore the existing relationship between Post-Acute COVID-19 Syndrome and stroke, delving into the epidemiology, prevalence, incidence, and related matters concerning the occurrence of stroke in individuals with Long COVID[2,3].

Long-term COVID, characterized by persistent symptoms and clinical findings that continue or develop after the acute phase of the infection has resolved, has garnered significant attention. Patients report a wide range of symptoms, including fatigue, dyspnea, "brain fog," and more[4]. Importantly, emerging evidence suggests a link between Post-Acute COVID-19 Syndrome and an increased risk of stroke, necessitating a thorough investigation into the mechanisms driving this association[5].

Epidemiologically, studies have begun to outline the prevalence and incidence of stroke among patients recovering from COVID-19. The incidence of stroke in this patient population appears elevated compared to historical controls, hinting at a possible direct or indirect effect of the virus or the immune response it elicits[6-8].

The precise mechanisms remain under investigation but may include endothelial dysfunction, hypercoagulability, and systemic inflammation, all of which are recognized features of COVID-19 that could predispose patients to thrombotic events such as stroke.

Prevalence data further elucidates the burden of this complication, with research indicating that a not-insignificant fraction of patients recovering from COVID-19 experience cerebrovascular events[7-9].

This correlation is particularly pronounced in severe cases of COVID-19 and among certain demographic groups, including older adults and those with pre-existing comorbidities. Such findings underscore the necessity for vigilant monitoring and management strategies for this at-risk population[10-12].

The pathophysiology linking COVID-19 and stroke involves a complex interplay of factors. The virus's impact on the vascular endothelium and a prothrombotic state suggest mechanisms through which COVID-19 might precipitate cerebrovascular accidents. Additionally, the role of systemic inflammation and immune-mediated damage provides further avenues for exploration. Understanding these pathways is critical for developing preventive and therapeutic interventions[13-15].

The implications of these findings are vast, extending beyond the immediate clinical management of patients to encompass public health strategies and healthcare resource allocation. As the pandemic evolves, so too does the understanding of its long-term impacts, including the risk of stroke among survivors. This requires ongoing research to refine risk stratification, improve patient outcomes, and guide health policy decisions[16-18].

The relationship between Post-Acute COVID-19 Syndrome and stroke embodies a significant concern within the broader context of the pandemic's aftermath. Current evidence points to an elevated risk of cerebrovascular events in individuals recovering from COVID-19, with substantial implications for patient care and healthcare systems worldwide[17-19].

Future research must continue to unravel the mechanisms underpinning this association, optimize management strategies for affected patients, and mitigate the long-term health consequences of this unprecedented global health crisis[20].

As of today, the state of knowledge underscores the critical need for multidisciplinary approaches to address the multifaceted challenges posed by Long COVID and its association with stroke[21]. Comprehensive studies exploring epidemiological trends, biological mechanisms, and effective interventions are paramount to navigating the post-pandemic era and ensuring robust public health responses to the lingering effects of SARS-CoV-2[22-24].

In this sense, the primary objective of the present review is to elucidate the complex molecular and pathophysiological mechanisms underlying the association between Post-Acute COVID-19 Syndrome, commonly referred to as Long COVID and the increased incidence of stroke among individuals recovering from COVID-19[25].

This review aims to synthesize current research findings to comprehensively understand how endothelial dysfunction, hypercoagulability, systemic inflammation, immune system dysregulation, and autonomic nervous system disruption contribute to the elevated stroke risk observed in Long COVID patients[23-26].

Further, the review seeks to identify gaps in the existing literature, encouraging future research endeavors that could lead to the development of targeted therapeutic interventions and management strategies[21,22].

By doing so, it aims to facilitate better clinical outcomes for patients experiencing the long-term sequelae of COVID-19 and ultimately reduce the morbidity and mortality associated with stroke in this vulnerable population.

METHODS

The research strategy employed for this study was meticulously designed to encompass an exhaustive review of literature across several distinguished databases known for their extensive collection of medical and scientific peer-reviewed publications. The databases selected for this comprehensive search included PubMed, Scopus, Scielo, Embase, and Web of Science, each renowned for their vast repository of scholarly articles. Google Scholar was also a supplementary resource for accessing the so-called gray literature, which often contains significant studies and reports unavailable in conventional academic journals. The focal point of this research was the intersection of Post-Acute COVID-19 Syndrome and Stroke, guiding the formulation of search parameters. A carefully curated set of keywords was deployed to optimize the search, comprising terms such as "post-acute Covid-19 syndrome," "long Covid," "long-haul Covid," "stroke," "acute cerebrovascular accident," and "cerebrovascular strokes." This strategic combination of keywords was instrumental in filtering the literature to include studies directly pertinent to the research objectives. To ensure a broad yet relevant data collection, the inclusion criteria were designed to be comprehensive, welcoming a variety of study designs, including systematic reviews, case-control studies, cross-sectional analyses, case series, and scholarly reviews. Such diversity in study types aimed to capture a spectrum of evidence and viewpoints regarding the nexus between Post-Acute COVID-19 Syndrome and cerebrovascular incidents. The literature review's evaluation and selection process were executed with strict adherence to methodological rigor. This involved a dual-review system, where pairs of reviewers independently evaluated each study's title and abstract for relevance and conformity to the predefined criteria. Discrepancies between reviewers were resolved through consultation with a third independent reviewer to reach a consensus, ensuring the selection was based on solid and unbiased judgment. This detailed and systematic approach to research methodology underpins the reliability and validity of the findings presented and ensures that the conclusions drawn from this study are grounded in a comprehensive and critically evaluated body of scientific evidence related to Post-Acute COVID-19 Syndrome and Stroke.

RESULTS AND DISCUSSION

The intricate relationship between Post-Acute COVID-19 Syndrome, often termed Long COVID, and the elevated risk of stroke in affected patients is an area of

intense research focus[27]. This relationship is underpinned by several molecular and pathophysiological mechanisms that contribute to an increased risk of cerebrovascular events. These mechanisms include endothelial dysfunction, hypercoagulability, systemic inflammation, and immune system dysregulation[28].

Endothelial Dysfunction

SARS-CoV-2, the virus responsible for COVID-19, interacts with angiotensin-converting enzyme 2 (ACE2) receptors to enter cells. These receptors are abundantly present on the endothelial cells lining the blood vessels[19-21]. The virus's entry leads to direct endothelial damage, disrupting the integrity of the vascular wall. This disruption can result in increased vascular permeability, leading to edema and a pro-thrombotic state, thereby elevating the risk of stroke[29].

Hypercoagulability

COVID-19 has been associated with a heightened state of coagulation, which manifests as elevated levels of fibrinogen, D-dimer, and other clotting factors. This hypercoagulable state increases the likelihood of thrombus formation within the cerebral vasculature, potentially leading to ischemic strokes[30-32]. The mechanisms driving this hypercoagulability include direct viral effects on the endothelium, cytokine storm-induced activation of the coagulation pathway, and platelet activation[24].

Systemic Inflammation

The immune response to SARS-CoV-2 infection can result in a cytokine storm, characterized by the excessive release of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 beta (IL-1β)[33]. This systemic inflammation can contribute to endothelial damage, enhance the coagulation cascade, and increase blood-brain barrier permeability, all of which can predispose patients to stroke[28-30].

Immune System Dysregulation

Long COVID features a prolonged and often aberrant immune response, with continued activation even after the acute infection has resolved. This dysregulated immune response can contribute to chronic inflammation and autoimmunity, further increasing the risk of vascular damage and stroke[8,13-15]. Autoantibodies against phospholipids, a characteristic of antiphospholipid syndrome, have been observed in some COVID-19 patients, suggesting a potential mechanism for stroke through the promotion of clot formation[34].

Autonomic Nervous System Disruption

Post-acute COVID-19 Syndrome has been linked to dysautonomia, which can affect cardiovascular regulation. Disruption in autonomic nervous system function may lead to alterations in blood pressure and heart rate, potentially contributing to stroke risk by affecting cerebral blood flow dynamics[35].

Stroke, Post-Acute COVID-19 Syndrome (Long COVID), and Gut microbiota

The interconnection between stroke, Post-Acute COVID-19 Syndrome (Long COVID), and alterations in the gut microbiota emerges as a complex and intriguing aspect of the multifaceted impact of SARS-CoV-2 infection[25-27]. Emerging research suggests that disruptions to the gut microbiome may play a significant role in the pathophysiology of acute COVID-19 and its long-term sequelae, potentially influencing the risk of cerebrovascular events such as stroke[36].

The gut microbiota is known to influence systemic inflammation and immune function profoundly. Changes in the composition of the gut microbiome, known as dysbiosis, can lead to increased intestinal barrier permeability (leaky gut), allowing microbial metabolites and endotoxins to enter the bloodstream. This translocation can trigger systemic inflammation, a key contributor to the pathogenesis of stroke and a known feature of severe COVID-19[37].

In the context of COVID-19, the virus and the body's response to it can lead to alterations in the gut microbiome[36]. For example, the use of antibiotics to treat secondary bacterial infections in COVID-19 patients, the direct invasion of gut epithelial cells by the virus via ACE2 receptors, and the impact of systemic inflammation on gut health can all contribute to significant changes in the microbiota. These changes can exacerbate systemic inflammation and potentially increase the risk of thrombosis and stroke[38].

Furthermore, the gut-brain axis, a complex communication network that links the enteric and central nervous systems, provides a pathway through which gut microbiota alterations could influence brain health and function[10-12]. Dysbiosis has been associated with increased levels of circulating pro-inflammatory cytokines, which can contribute to endothelial dysfunction and hypercoagulability, key risk factors for stroke[39].

In patients with Long COVID, persistent such as fatigue, cognitive impairment ("brain fog"), and others may be partly driven by ongoing symptoms and immune dysregulation, in which the gut microbiota could play a crucial role[26-38]. Therefore, understanding the changes in the gut microbiome after COVID-19 and their potential contribution to the increased risk of stroke is of paramount importance[40-42].

Interventions aimed at restoring a healthy gut microbiota, such as probiotics, prebiotics, or dietary modifications, may offer the therapeutic potential to reduce inflammation, improve immune function, and potentially decrease the risk of stroke in individuals with Post-Acute COVID-19 Syndrome[31-33,43]. Further research into the gut microbiome's role in the pathophysiology of COVID-19 and its long-term effects will be crucial in developing comprehensive strategies to mitigate the risk of stroke and other cardiovascular complications associated with the disease[44-46].

Research has indicated that the inflammatory response triggered by COVID-19, along with the hypercoagulable state it induces, can significantly heighten the risk of stroke, especially in individuals already predisposed to the factors above[18]. Furthermore, individuals who experienced severe COVID-19 symptoms requiring hospitalization, particularly those needing intensive care or mechanical ventilation, are at a higher risk for developing cerebrovascular events in the post-acute phase of the disease[38-40].

Additionally, certain demographic groups, including men and those of specific ethnic backgrounds that traditionally have higher predispositions to cardiovascular diseases, might be at an increased risk[8-11]. Understanding these risk factors is crucial for healthcare providers to identify high-risk individuals for more vigilant monitoring and implementation of preventive strategies to mitigate the risk of stroke in patients with Post-Acute COVID-19 Syndrome[4,39-42].

Young adults, Post-Acute COVID-19, and Stroke

Stroke occurring in young adults with Post-Acute COVID-19 Syndrome is a concerning phenomenon that diverges from the traditional risk profile associated with cerebrovascular events. This trend can be attributed to several factors inherent to the pathophysiology of COVID-19 and its aftermath[5-8].

Firstly, COVID-19 has been associated with a hypercoagulable state characterized by increased blood clotting. This condition is precipitated by the virus's effect on the endothelial cells lining the blood vessels, leading to endothelial dysfunction, inflammation, and coagulation pathway activation[14]. Even in younger individuals who typically have a lower risk of stroke, this hypercoagulable state can lead to the formation of clots that may cause ischemic stroke[22].

Secondly, the inflammatory response to COVID-19, including the release of pro-inflammatory cytokines (cytokine storm), can contribute to a prothrombotic environment. This systemic inflammation can damage vascular integrity and promote clot formation, increasing stroke risk in patients regardless of age[47].

Thirdly, COVID-19 has been shown to cause direct and indirect effects on the cardiovascular system, including myocardial injury, which can lead to cardiac arrhythmias. Such arrhythmias, especially if new or poorly controlled, can increase the risk of forming clots that could travel to the brain, resulting in a stroke[27-30].

Additionally, there's growing evidence suggesting that COVID-19 might trigger an autoimmune response in some individuals, leading to an increased tendency for blood clotting, further elevating stroke risk in a demographic that typically would not be as susceptible[15,16].

Lastly, lifestyle changes during the pandemic, such as decreased physical activity, increased sedentary behavior, and changes in diet may have indirectly contributed to the risk factors associated with stroke in young adults[10].

In summary, the occurrence of stroke in young adults with Post-Acute COVID-19 Syndrome likely results from a combination of hypercoagulability, systemic inflammation, direct cardiovascular effects, potential autoimmune responses, and lifestyle factors exacerbated by the pandemic[44]. These insights underscore the importance of monitoring young adults recovering from COVID-19 for signs of cerebrovascular impairment and implementing preventive strategies to mitigate these risks[31-33].

To mitigate the risk of cerebrovascular impairment in young adults recovering from COVID-19, a multifaceted approach that encompasses lifestyle modifications, medical interventions, and monitoring for early signs of complications is essential. The following strategies can play a crucial role in prevention[5-7]:

Lifestyle Modifications

Encouraging a healthy lifestyle is fundamental. This includes a balanced diet rich in fruits, vegetables, whole grains, and lean proteins to reduce inflammation and support vascular health[36]. Regular physical activity, even mild to moderate exercise, can improve cardiovascular function and reduce stroke risk. Additionally, stress reduction techniques such as mindfulness, yoga, or meditation can help manage stress, which is known to be a risk factor for stroke[39-41].

Monitoring and Management of Cardiovascular Risk Factors

Close monitoring and management of pre-existing conditions such as hypertension, diabetes, obesity, and high cholesterol are vital. Young adults recovering from COVID-19 should have regular check-ups to monitor these conditions and adjust medications as necessary to keep them well controlled[23].

Avoidance of Smoking and Limitation of Alcohol Intake

Smoking cessation and limiting alcohol consumption are critical, as both smoking and excessive alcohol use are significant risk factors for stroke. Providing resources and support for smoking cessation and recommending moderation in alcohol consumption can be beneficial[30-32].

Education on Recognizing Stroke Symptoms

Educating recovering COVID-19 patients about the signs and symptoms of a stroke — such as sudden numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion; trouble speaking or understanding speech; visual disturbances; trouble walking; dizziness; or severe headache with no known cause — can ensure timely medical intervention, which is crucial for a positive outcome following a stroke[48-50].

Regular Medical Follow-ups

Regular follow-ups with healthcare providers can help in the early identification and management of post-COVID symptoms that may increase stroke risk. This includes monitoring for and addressing any lingering effects of COVID-19 that could contribute to vascular issues[34,51].

Use of Anticoagulants in High-risk Individuals

For individuals at high risk of thrombosis, healthcare providers may consider the prophylactic use of anticoagulants. This decision should be made on an individual basis, weighing the benefits against the risks of bleeding[20-22,52].

Management of Post-COVID Symptoms

Addressing chronic inflammation and other post-COVID conditions that may contribute to an increased risk of stroke is crucial. This may involve anti-inflammatory treatments, physical therapy, and other supportive measures to alleviate symptoms[49].

Research and Public Health

Continued research into the long-term effects of COVID-19, including its impact on young adults and risk of stroke, is essential. Advocacy for public health measures to control the spread of COVID-19 and vaccination against the virus can also play a role in reducing the overall burden of disease and its long-term complications[46-48].

Implementing these preventative strategies requires a coordinated effort from healthcare providers, patients, and public health officials to effectively reduce the risk of cerebrovascular impairment in young adults recovering from COVID-19[53,54].

CONCLUSION

In conclusion, the molecular and pathophysiological mechanisms connecting Long COVID to an increased risk of stroke are multifaceted, involving endothelial dysfunction, hypercoagulability, systemic inflammation, immune system dysregulation, and autonomic nervous system disruption.

Understanding these mechanisms is crucial for developing targeted interventions to mitigate the risk of cerebrovascular events in patients with Post-Acute COVID-19 Syndrome. Ongoing research into these pathways and their interactions will be vital in unraveling the complex relationship between Long COVID and stroke, ultimately guiding clinical management and improving patient outcomes.

REFERENCES

1. Moldovan AF, Moga I, Moga T, Ghitea EC, Babes K, Ghitea TC. Assessing the Risk of Stroke in the Elderly in the Context of Long-COVID, Followed Through the Lens of Family Medicine. In Vivo. 2023 Sep-Oct;37(5):2284-2295. doi: 10.21873/invivo.13331.
2. Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, Harrison PJ. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022 Oct;9(10):815-827. doi: 10.1016/S2215-0366(22)00260-7.
3. Dioh W, Chabane M, Tourette C, Azbekyan A, Morelot-Panzini C, Hajjar LA, Lins M, Nair GB, Whitehouse T, Mariani J, Latil M, Camelo S, Lafont R, Dilda PJ, Veillet S, Agus S. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomized controlled trial. Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
4. Flud VV, Shcherbuk YA, Shcherbuk AY, Leonov VI, Al-Sahli OA. [Neurological complications and consequences of new coronavirus COVID-19 infection in elderly and old patients (literature review).]. Adv Gerontol. 2022;35(2):231-242. Russian.
5. Xie Y, Choi T, Al-Aly Z. Association of Treatment with Nirmatrelvir and the Risk of Post-COVID-19 Condition. JAMA Intern Med. 2023 Jun 1;183(6):554-564. doi: 10.1001/jamainternmed.2023.0743.
6. Mazzitelli M, Trunfio M, Sasset L, Leoni D, Castelli E, Lo Menzo S, Gardin S, Putaggio C, Brundu M, Garzotto P, Cattelan AM. Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA. Viruses. 2022 Feb 28;14(3):493. doi: 10.3390/v14030493.
7. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8.
8. Davoudi F, Miyashita S, Yoo TK, Lee PT, Foster GP. An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine. Crit Pathw Cardiol. 2022 Sep 1;21(3):123-129. doi: 10.1097/HPC.0000000000000290.
9. Ioannou GN, Baraff A, Fox A, Shahoumian T, Hickok A, O'Hare AM, Bohnert ASB, Boyko EJ, Maciejewski ML, Bowling CB, Viglianti E, Iwashyna TJ, Hynes DM. Rates and Factors Associated with Documentation of Diagnostic Codes for Long COVID in the National Veterans Affairs Health Care System. JAMA Netw Open. 2022 Jul 1;5(7): e2224359. doi: 10.1001/jamanetworkopen.2022.24359.
10. Wanga V, Chevinsky JR, Dimitrov LV, Gerdes ME, Whitfield GP, Bonacci RA, Nji MAM, Hernandez-Romieu AC, Rogers-Brown JS, McLeod T, Rushmore J, Lutfy C, Bushman D, Koumans E, Saydah S, Goodman AB, Coleman King SM, Jackson BR, Cope JR. Long-

Term Symptoms Among Adults Tested for SARS-CoV-2 - United States, January 2020-April 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1235-1241. doi: 10.15585/mmwr.mm7036a1.

11. Hill EL, Mehta HB, Sharma S, Mane K, Singh SK, Xie C, Cathey E, Loomba J, Russell S, Spratt H, DeWitt PE, Ammar N, Madlock-Brown C, Brown D, McMurry JA, Chute CG, Haendel MA, Moffitt R, Pfaff ER, Bennett TD; N3C Consortium; and the RECOVER Consortium. Risk factors associated with post-acute sequelae of SARS-CoV-2: an N3C and NIH RECOVER study. BMC Public Health. 2023 Oct 25;23(1):2103. doi: 10.1186/s12889-023-16916-w.
12. Chachkhiani D, Soliman MY, Barua D, Isakadze M, Villemarette-Pittman NR, Devier DJ, Lovera JF. Neurological complications in a predominantly African American sample of COVID-19 predict worse outcomes during hospitalization. Clin Neurol Neurosurg. 2020 Oct; 197:106173. doi: 10.1016/j.clineuro.2020.106173.
13. Lukiw WJ, Jaber VR, Pogue AI, Zhao Y. SARS-CoV-2 Invasion and Pathological Links to Prion Disease. Biomolecules. 2022 Sep 7;12(9):1253. doi: 10.3390/biom12091253.
14. Wang S, Farland LV, Gaskins AJ, Mortazavi J, Wang YX, Tamimi RM, Rich-Edwards JW, Zhang D, Terry KL, Chavarro JE, Missmer SA. Association of laparoscopically confirmed endometriosis with long COVID-19: a prospective cohort study. Am J Obstet Gynecol. 2023 Jun;228(6):714.e1-714.e13. doi: 10.1016/j.ajog.2023.03.030.
15. Cohen K, Ren S, Heath K, Dasmariñas MC, Jubilo KG, Guo Y, Lipsitch M, Daugherty SE. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2022 Feb 9;376: e068414. doi: 10.1136/bmj-2021-068414.
16. Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, Bontempo G, Marrella F, Tommasini A, Fabris M, Curcio F, Isola M, Tascini C. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021 Oct;27(10):1507-1513. doi: 10.1016/j.cmi.2021.05.033.
17. Zielińska-Turek J, Jasińska A, Kołakowska J, Szadurska J, Kosior DA, Dorobek M. Clinical features of neurological patients with coronavirus 2019: an observational study of one centre. Neurol Neurochir Pol. 2021;55(2):195-201. doi: 10.5603/PJNNS.a2021.0011.
18. Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Ottaviani D, Chowdhury A, Merry E, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Liñan R, Rossi S, Carmona-García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Saponara M, Cruz CA, García-Illescas D, Felip E, Roqué Lloveras A, Sharkey R, Roldán E, Reyes R, Earnshaw I, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Cantini L, Filetti M, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Van Hemelrijck M, Diamantis

N, Newsom-Davis T, Gennari A, Cortellini A; OnCovid study group. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol. 2021 Dec;22(12):1669-1680. doi: 10.1016/S1470-2045(21)00573-8.

19. Wang S, Quan L, Chavarro JE, Slopen N, Kubzansky LD, Koenen KC, Kang JH, Weisskopf MG, Branch-Elliman W, Roberts AL. Associations of Depression, Anxiety, Worry, Perceived Stress, and Loneliness Prior to Infection with Risk of Post-COVID-19 Conditions. JAMA Psychiatry. 2022 Nov 1;79(11):1081-1091. doi: 10.1001/jamapsychiatry.2022.2640.
20. Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ. 2022 Feb 16;376:e068993. doi: 10.1136/bmj-2021-068993.
21. Marietta M, Vandelli P, Mighali P, Vicini R, Coluccio V, D'Amico R; COVID-19 HD Study Group. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. Trials. 2020 Jun 26;21(1):574. doi: 10.1186/s13063-020-04475-z.
22. Khedr EM, Shoyb A, Mohammaden M, Saber M. Acute symptomatic seizures, and COVID-19: Hospital-based study. Epilepsy Res. 2021 Aug; 174:106650. doi: 10.1016/j.eplepsyres.2021.106650.
23. Noviello D, Costantino A, Muscatello A, Bandera A, Consonni D, Vecchi M, Basilisco G. Functional gastrointestinal and somatoform symptoms five months after SARS-CoV-2 infection: A controlled cohort study. Neurogastroenterol Motil. 2022 Feb;34(2): e14187. doi: 10.1111/nmo.14187.
24. Bartczak KT, Milkowska-Dymanowska J, Piotrowski WJ, Bialas AJ. The utility of telemedicine in managing patients after COVID-19. Sci Rep. 2022 Dec 10;12(1):21392. doi: 10.1038/s41598-022-25348-2.
25. Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022 Jul; 103:154-162. doi: 10.1016/j.bbi.2022.04.013.
26. Samsonia M, Kandelaki M, Baratashvili N, Gvaramia L. Neuroprotective and antioxidant potential of montelukast-acetylcysteine combination therapy for brain protection in patients with covid-19 induced pneumonia. Georgian Med News. 2023 Feb;(335):111-118.
27. Kihira S, Schefflein J, Mahmoudi K, Rigney B, N Delman B, Mocco J, Doshi A, Belani P. Association of Coronavirus Disease (COVID-19) With Large Vessel Occlusion Strokes: A Case-Control Study. AJR Am J Roentgenol. 2021 Jan;216(1):150-156. doi: 10.2214/AJR.20.23847.
28. Mathew T, John SK, Sarma G, Nadig R, Kumar R S, Murgod U, Mahadevappa M, Javali M, Acharya PT, Hosurkar G, Krishnan P, Kamath V, Badachi S, Souza DD, Iyer RB, Nagarajaiah RK, Anand B, Kumar S, Kodapala S, Shivde S, Avati A, Baddala R, Potharlanka PB, Pavuluri S, Varidireddy A, Awatare P, Shobha N, Renukaradhya U,

Kumar SP, Ramachandran J, Arumugam R, Deepalam S, Kumar S, Huded V. COVID-19-related strokes are associated with increased mortality and morbidity: A multicenter comparative study from Bengaluru, South India. Int J Stroke. 2021 Jun;16(4):429-436. doi: 10.1177/1747493020968236.

29. Davoudi F, Miyashita S, Yoo TK, Lee PT, Foster GP. An Insight into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine. Crit Pathw Cardiol. 2022 Sep 1;21(3):123-129. doi: 10.1097/HPC.0000000000000290.
30. Li YE, Wang S, Reiter RJ, Ren J. Clinical cardiovascular emergencies, and the cellular basis of COVID-19 vaccination: from dream to reality? Int J Infect Dis. 2022 Nov; 124:1-10. doi: 10.1016/j.ijid.2022.08.026.
31. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernán MA, Lipsitch M, Kohane I, Netzer D, Reis BY, Balicer RD. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021 Sep 16;385(12):1078-1090. doi: 10.1056/NEJMoa2110475.
32. Baranauskas MN, Carter SJ. Evidence for impaired chronotropic responses to and recovery from 6-minute walk test in women with post-acute COVID-19 syndrome. Exp Physiol. 2022 Jul;107(7):722-732. doi: 10.1113/EP089965.
33. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission, and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
34. Román GC, Gracia F, Torres A, Palacios A, Gracia K, Harris D. Acute Transverse Myelitis (ATM): Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events with the ChAdOx1 nCoV-19 Vaccine (AZD1222). Front Immunol. 2021 Apr 26; 12:653786. doi: 10.3389/fimmu.2021.653786.
35. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389.
36. Stowe J, Miller E, Andrews N, Whitaker HJ. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England. PLoS Med. 2023 Jun 7;20(6): e1004245. doi: 10.1371/journal.pmed.1004245.
37. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics. 2020 Nov 1;52(11):549-557. doi: 10.1152/physiolgenomics.00089.2020.
38. Mazzitelli M, Trunfio M, Sasset L, Leoni D, Castelli E, Lo Menzo S, Gardin S, Putaggio C, Brundu M, Garzotto P, Cattelan AM. Factors Associated with Severe COVID-19

and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA. Viruses. 2022 Feb 28;14(3):493. doi: 10.3390/v14030493.

39. Khunti S, Khunti N, Seidu S, Khunti K. Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19). Diabetes Obes Metab. 2020 Oct;22(10):1942-1945. doi: 10.1111/dom.14062.
40. Reis Carneiro D, Rocha I, Habek M, Helbok R, Sellner J, Struhal W, Wenning G, Fanciulli A. Clinical presentation, and management strategies of cardiovascular autonomic dysfunction following a COVID-19 infection - A systematic review. Eur J Neurol. 2023 May;30(5):1528-1539. doi: 10.1111/ene.15714.
41. Bárczi E, Varga V, Nagy A, Eszes N, Jáky-Kováts Z, Müller V, Bohács A. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients. Immun Inflamm Dis. 2022 Aug;10(8): e646. doi: 10.1002/iid3.646.
42. Carod-Artal FJ. Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved. Rev Neurol. 2021 Jun 1;72(11):384-396. doi: 10.33588/rn.7211.2021230.
43. Doyle MF. Central nervous system outcomes of COVID-19. Transl Res. 2022 Mar; 241:41-51. doi: 10.1016/j.trsl.2021.09.002.
44. Golla R, Vuyyuru SK, Kante B, Kedia S, Ahuja V. Disorders of gut-brain interaction in post-acute COVID-19 syndrome. Postgrad Med J. 2023 Jul 21;99(1174):834-843. doi: 10.1136/pmj-2022-141749.
45. Bicknell B, Liebert A, Borody T, Herkes G, McLachlan C, Kiat H. Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome. Int J Mol Sci. 2023 May 31;24(11):9577. doi: 10.3390/ijms24119577.
46. Zhao S, Toniolo S, Hampshire A, Husain M. Effects of COVID-19 on cognition and brain health. Trends Cogn Sci. 2023 Nov;27(11):1053-1067. doi: 10.1016/j.tics.2023.08.008.
47. León-Moreno LC, Reza-Zaldívar EE, Hernández-Sapiéns MA, Villafaña-Estarrón E, García-Martin M, Ojeda-Hernández DD, Matias-Guiu JA, Gomez-Pinedo U, Matias-Guiu J, Canales-Aguirre AA. Mesenchymal Stem Cell-Based Therapies in the Post-Acute Neurological COVID Syndrome: Current Landscape and Opportunities. Biomolecules. 2023 Dec 20;14(1):8. doi: 10.3390/biom14010008.
48. Szabo S, Zayachkivska O, Hussain A, Muller V. What is really 'Long COVID'? Inflammopharmacology. 2023 Apr;31(2):551-557. doi: 10.1007/s10787-023-01194-0.
49. Peron JPS. Direct and indirect impact of SARS-CoV-2 on the brain. Hum Genet. 2023 Aug;142(8):1317-1326. doi: 10.1007/s00439-023-02549-x.
50. Yong SJ. Persistent Brainstem Dysfunction in Long-COVID: A Hypothesis. ACS Chem Neurosci. 2021 Feb 17;12(4):573-580. doi: 10.1021/acschemneuro.0c00793.

51. Moghimi N, Di Napoli M, Biller J, Siegler JE, Shekhar R, McCullough LD, Harkins MS, Hong E, Alaouieh DA, Mansueto G, Divani AA. The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection. Curr Neurol Neurosci Rep. 2021 Jun 28;21(9):44. doi: 10.1007/s11910-021-01130-1.
52. Teo WP, Goodwill AM. Can exercise attenuate the negative effects of long COVID syndrome on brain health? Front Immunol. 2022 Sep 16; 13:986950. doi: 10.3389/fimmu.2022.986950.
53. Maiese K. Cellular Metabolism: A Fundamental Component of Degeneration in the Nervous System. Biomolecules. 2023 May 11;13(5):816. doi: 10.3390/biom13050816.
54. Kiyak C, Ijezie OA, Ackah JA, Armstrong M, Cowen J, Cetinkaya D, Burianová H, Akudjedu TN. Topographical Distribution of Neuroanatomical Abnormalities Following COVID-19 Invasion: A Systematic Literature Review. Clin Neuroradiol. 2024 Mar;34(1):13-31. doi: 10.1007/s00062-023-01344-5.